Rutgers, the State University of New Jersey

Massachusetts Institute of Technology

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Broad Institute, Inc.

Harvard College

Skolkovo Institute of Science and Technology

Abudayyeh, Omar O.

Joung, Julia

Minakhin, Leonid

Makarova, Kira S.

Severinov, Konstantin

Semenova, Ekaterina

Lander, Eric S.

Shmakov, Sergey

Konermann, Silvana

Konstantin Severinov

Feng Zhang

Eugene Koonin

Kira S Makarova

Yuri I Wolf

Sergey Shmakov

Ekaterina Semenova

Omar O Abudayyeh

Jonathan S Gootenberg

Richard H Ebright

Silvana Konermann

Julia Joung

Leonid Minakhin

Eric Lander

David Arthur Scott

Winston X Yan

Eric S Lander

Aaron Smargon

Neena Pyzocha

David Cox

Jayanta Mukhopadhyay

Olga Pavlova

Elena Sineva

Disclosed here is a method of identifying novel CRISPR effectors, comprising: identifying sequences in a genomic or metagenomic database encoding a CRISPR array; identifying one or more Open Reading Frames (ORFs) in said selected sequences within 10 kb of the CRISPR array; discarding all loci encoding proteins which are assigned to known CRISPR-Cas subtypes and, optionally, all loci encoding a protein of less than 700 amino acids; and identifying putative novel CRISPR effectors, and optionally classifying them based on structure analysis.

Methods for identifying class 2 crispr-cas systems

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

CRISPR enzymes and systems

The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

A nucleic acid sequence is provided, encoding at least one of a precursor of a lariat peptide, a processing factor of a lariat peptide, and an export factor of a lariat peptide, wherein the lariat peptide is a non-MccJ25 lariat peptide according to general structural formula (I) Also provided are biosynthesis systems useful for the synthesis of peptides according to formula (I), and methods of detecting and identifying nucleic acid sequences encoding the disclosed proteins. 

Nucleic acid sequences for biosynthesis of non-MccJ25-related lariat peptides

The invention provides a method of inhibiting a bacterial RNA polymerases. The invention has applications in control of bacterial RNA polymerase activity, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.

Non-MCCJ25-related lariat-peptide inhibitors of bacterial RNA polymerase

Analogs of bacteriocidal peptide microcin J25 (MccJ25) are provided that have an amino acid sequence that differs from that of MccJ25 by having at least one amino acid substitution; and that inhibit bacterial cell growth with a potency at least equal to that of MccJ25.

Mutational derivatives of microcin J25

Growing community of inventors

Piscataway, NJ, United States of America

Konstantin Severinov